Business Context and Reporting Period
Pliant Therapeutics, Inc. (PLRX) filed a Form 8-K on August 7, 2025, to announce its financial results for the second quarter ended June 30, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. The document serves solely as a notification that the Q2 2025 results have been issued.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in this Current Report and its exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other filings. No specific guidance, outlook, management commentary, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 7, 2025) for actual Q2 2025 financial figures.
- Verify the company's cash position and burn rate in the full press release to assess runway.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the company provided updated full-year guidance in the referenced press release.